Dr. Reddy’s Laboratories announces the launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market

Spread the love

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Bortezomib for Injection 3.5 mg, the generic equivalent of Velcade® (bortezomib) Injection, in the U.S. market approved by the U.S. Food and Drug Administration (USFDA).

The Velcade® Brand and generic had U.S. sales of approximately $1.2 billion MAT for the most recent twelve months ending in May 2022 according to IQVIA Health*.

Dr. Reddy’s Bortezomib for Injection, is supplied in a 3.5 mg per 10 mL single-dose vial presentation for subcutaneous (SQ) or intravenous (IV) use.

Click here for full prescribing information: https://www.drreddys.com/pi/dr-reddy-bortezomib-3.5mg-iv- sc-vial-leaflet.pdf

Velcade is a trademark of Takeda Pharmaceuticals U.S.A., Inc.

*IQVIA Retail and Non-Retail MAT May 2022

RDY-0722-430

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com


Spread the love
Ad Widget

Recommended For You

About the Author: mundadugu_english

Leave a Reply

Your email address will not be published. Required fields are marked *